Millendo Therapeutics Stock Price

0.03 (2.83%)
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Millendo Therapeutics Inc MLND NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.03 2.83% 1.09 08:01:02
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
1.08 1.09 0.01 - -
Trades Volume Avg Volume 52 Week Range
28 10,794 738,665 1.06 - 3.64
Last Trade Time Type Quantity Stock Price Currency
08:01:02 formt 100 $ 1.09 USD

Millendo Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 20.71M 19.00M 18.89M $ - $ - -3.26 -0.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Millendo Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MLND Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.,690-0.15-12.1%
1 Month2.202.891.061.361,419,634-1.11-50.45%
3 Months1.822.891.061.75864,995-0.73-40.11%
6 Months1.682.891.061.76665,095-0.59-35.12%
1 Year1.793.641.061.99839,013-0.70-39.11%
3 Years10.156717.341.062.45422,016-9.07-89.27%
5 Years10.156717.341.062.45422,016-9.07-89.27%

Millendo Therapeutics Description

Millendo Therapeutics Inc is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases. Its lead asset, livoletide, is an unacylated ghrelin analogue being developed for the treatment of Prader-Willi syndrome (PWS), a rare genetic disease characterized by hyperphagia, a chronic unrelenting hunger, that leads to obesity, metabolic dysfunction, reduced quality of life and early mortality. The company is also developing nevanimibe, an ACAT1 inhibitor for the treatment of two orphan adrenal diseases: classic congenital adrenal hyperplasia (CAH) and endogenous Cushing's syndrome (CS).

Your Recent History
Millendo T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.